Innovent and HUTCHMED Report P-II/III (FRUSICA-2) Trial Data of Sintilimab + Fruquintinib for Metastatic Renal Cell Carcinoma (RCC)
Shots:
- Innovent & HUTCHMED have reported P-II/III (FRUSICA-2) trial data assessing sintilimab + fruquintinib vs axitinib/everolimus as 2L therapy for LA/M RCC in China; NDA of sintilimab + Yervoy for resectable MSI-H/dMMR colon cancer is under NMPA priority review
- Trial met its 1EP of improved PFS per RECIST 1.1 & demonstrated improvements in 2EPs, incl. ORR & DoR; full data to be presented at future conferences & shared with global health authorities for potential NDA filings in upcoming months
- Additionally, sintilimab is being evaluated as a 2L monotx. in P-II trial for ESCC & P-III trial for squamous NSCLC in pts who had disease progression after Pt-based CT, both of which have met their 1EPs
Ref: Prnewswire | Image: Innovent & HUTCHMED
Related News:- Innovent Reports the NMPA Approval of Sycume for Thyroid Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
